Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset

With three biotechs trading up after NASDAQ debuts, sustained positive performance could further open window 

Indiana-based developer of long-acting peptide therapeutics is latest mid-to-late-stage biotech to seek NASDAQ listing

Pair of well-funded late-stage biotechs seek NASDAQ listings, Shanghai cancer company prices deal in Hong Kong

Moderna’s mResvia is its first mRNA vaccine approved outside COVID-19 pandemic

Company opens the door to biosimilars on its major formularies while partnering with AbbVie on a co-branded Humira

Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more

Plus: CEO changes at Lonza and Black Diamond, and updates from ImmunoGen, BenevolentAI and Nilogen

Selections underline difficulty in predicting how Inflation Reduction Act will be implemented

Red Tree branches beyond West Coast sweet spot to co-lead with RA Capital in backing Biocon spinout